Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

← catalyst calendar

NCT07777822 · readout ≤ 1,167 d

Sponsored by Revolution Medicines, Inc. (industry) · RVMD — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · Double · Treatment

Enrollment

430estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-20

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-08-14

actual

When the study began enrolling

Primary completion

Oct 2029

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Feb 2031

estimated

The whole study's end, after follow-up

First posted

2026-08-20

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-20

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

NSCLC
Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer NSCLC
Non-Squamous Non Small Cell Lung Cancer
Lung Cancer (NSCLC)
Metastatic NSCLC - Non-Small Cell Lung Cancer
Metastatic Non-Squamous Non-Small Cell Lung Cancer

Interventions

Drug: zoldonrasib
Drug: Placebo
Drug: pembrolizumab
Drug: pemetrexed + cisplatin /carboplatin — also filed as Platinum-based chemotherapy doublet

Primary outcome

what the primary-completion date above is the date OF

Progression free survival (PFS)

measured Up to approximately 5 years

Permalink · RVMD's whole pipeline · Catalyst calendar · Every registered study · What changed